Alzheimer's Disease, ß-Amyloidosis, and Aging
Authors:
- Isabel RubioIRIsabel Rubio
- Carmen BayonCBCarmen Bayon
- 1 January 1994
- journal article
- review article
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
- Vol. 5 (4) , 275-92
Abstract
Alzheimer's disease (AD) is rapidly moving from the obscure category of degenerative diseases to the more precise one of metabolic disorders. Recent discoveries have substantiated the hypothesis that AD results from the deposition of beta-amyloid, which is formed by polymers of a proteolytic fragment of the amyloid protein precursor (APP), and may induce intraneuronal aggregation of the microtubule-associated protein tau into paired helical filaments and neuronal death. There is also evidence that AD is a heterogeneous age-related disorder of multifactorial origin, which may arise as a consequence of point mutations of genes encoding APP or other proteins involved in its metabolism (familial AD), or a combination of genetic and non-genetic factors (sporadic AD). Familial AD displays genetic and phenotypic heterogeneity, meaning that mutations of different genes may cause the AD phenotype, and that different mutations of the same gene may cause phenotypically distinct disorders, including Alzheimer-type dementia and cerebral amyloid angiopathy with cerebral hemorrhages and stroke. On the other hand, aging, gender, head trauma, and variants of the apolipoprotein E gene have been shown to increase the risk of developing the more prevalent sporadic form of AD. The mechanisms by which these factors influence amyloidogenesis are beginning to be understood, and this will provide a rational basis for future therapy. Knowledge of the molecular basis of AD would eventually allow accurate risk prediction before the disease becomes clinically apparent, and better chances for early treatment and prevention.Keywords
This publication has 100 references indexed in Scilit:
- Genetic associations with human longevity at the APOE and ACE lociNature Genetics, 1994
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993
- Activation of the Secretory Pathway Leads to a Decrease in the Intracellular Amyloidogenic Fragments Generated from the Amyloid Protein PrecursorBiochemical and Biophysical Research Communications, 1993
- A novel silent variant at codon 711 and a variant at codon 708 of the APP sequence detected in Spanish Alzheimer and control casesNeuroscience Letters, 1993
- Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with Alzheimer's diseaseNeuroscience Letters, 1992
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- Alzheimer's disease amyloid β-clipping enzyme (APP secretase): Identification, purification, and characterization of the enzymeBiochemical and Biophysical Research Communications, 1991
- Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's diseaseNature, 1991
- In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to alzheimer's disease β-proteinBiochemical and Biophysical Research Communications, 1986
- Aging: A Theory Based on Free Radical and Radiation ChemistryJournal of Gerontology, 1956